BioSpace News Archive

VarmX today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).

Trevi Therapeutics, Inc. today announced that on March 7, 2023, the United States Patent and Trademark Office (“USPTO”) issued a notice of allowance for nalbuphine ER’s method of treatment of chronic cough in IPF.

Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 33rd Annual Oppenheimer Healthcare Conference taking place March 13-15, 2023.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, launches a number of events to raise awareness for the importance of early detection of colorectal cancer with physicians and medical professionals, but also with patients, their families, caregivers and the general public in Germany.

Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating BAT8008, an antibody-drug conjugate that targets Trop2.

JW Therapeutics announced the initiation of clinical study of Carteyva® for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.

Tessa Therapeutics Ltd. announced entry into a Cooperative Research and Development Agreement with the U.S. National Cancer Institute, part of the National Institutes of Health, to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, in multiple subtypes of non-Hodgkin lymphoma.

STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).

BlueWind Medical, Ltd. is pleased to announce that the American Medical Association has issued a new Current Procedural Terminology code for the subfascial implantation of a tibial neuromodulation device for Overactive Bladder.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.